Emile Voest
Just one WGS test is enough to reveal everything you need to know to provide a patient with metastatic cancer with targeted treatment, be it a registered therapy or part of a research trial.
Back to newsMore news
Why genomes need clinical data: new Nature study uses Hartwig real world data to test a prostate cancer biomarker
Understanding prostate cancer’s clinical heterogeneity A new study in Nature investigates the mutational processes behind prostate cancer’s clinical heterogeneity and …
Predicting therapy success based on gene expression
In addition to Whole Genome Sequencing of DNA, Hartwig Medical Foundation performs Whole Transcriptome Sequencing of RNA. Researcher Marjolein Lansbergen …
Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This …
We are proud that we succeeded in implementing the complete DNA test in standard of care diagnostics, together with Hartwig Medical Foundation. Moreover, the test produces vital information for a learning healthcare system in oncology. We will be able to treat future patients even more effectively.